COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
31/08/2026
- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total [...]
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
31/08/2026
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high [...]
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
31/08/2026
Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data [...]
Revelyx Bio Launches to Advance YY003, an Investigational Recombinant Botulinum Toxin Type A in a Ready-to-Use Liquid Formulation
31/08/2026
Company aims to deliver the first FDA-approved recombinant botulinum neurotoxin type A (rBoNT/A) Phase II study in moderate-to-severe glabellar lines completed; topline data expected in Q3 2026 Dustin Sjuts, former [...]
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
31/08/2026
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) [...]
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
31/08/2026
Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026 CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage [...]
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
31/08/2026
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
31/08/2026
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated [...]
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
31/08/2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/ European Renal Association (ERA) [...]
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
31/08/2026
TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related [...]
Allogene Therapeutics Announces Participation in September Investor Conference
31/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
31/08/2026
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure THE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results [...]
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
31/08/2026
Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan. While ADHD is often [...]
OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company
31/08/2026
Customer selects OneMedNet for the full-fidelity studies and regulatory decision-grade quality required to develop AI models that accelerate drug development MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet [...]
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
31/08/2026
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, [...]
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
31/08/2026
Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market [...]
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
31/08/2026
Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of [...]
SEMCAP Beauty & Wellness Leads Funding Round For Healf
31/08/2026
SEMCAP Beauty & Wellness leads investment in Healf, the personalized wellbeing platform helping consumers make more confident decisions about their health. Healf combines expert curation, diagnostics, wearable [...]
Persevere Therapeutics Announces Appointment of James Barlow to Board of Directors
31/08/2026
Chesterbrook, PA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a clinical-stage oncology company developing misetionamide — a first-in-class inhibitor of MYC, historically viewed as [...]

Pages